Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.

PLoS Med. 2012;9(3):e1001196. doi: 10.1371/journal.pmed.1001196. Epub 2012 Mar 27.

PMID:
22479156
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, Lazzarin A, Garcia F, Ellefsen K, Podzamczer D, van Lunzen J, Arastéh K, Schürmann D, Clotet B, Hardy WD, Mitsuyasu R, Moyle G, Plettenberg A, Fisher M, Fätkenheuer G, Fischl M, Taiwo B, Baksaas I, Jolliffe D, Persson S, Jelmert O, Hovden AO, Sommerfelt MA, Wendel-Hansen V, Sørensen B.

Lancet Infect Dis. 2014 Apr;14(4):291-300. doi: 10.1016/S1473-3099(13)70343-8. Epub 2014 Feb 11.

PMID:
24525316
[PubMed - indexed for MEDLINE]
3.

Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ.

PLoS Med. 2004 Dec;1(3):e64. Epub 2004 Dec 28.

PMID:
15630469
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
[PubMed - indexed for MEDLINE]
5.

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.

Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S; CNA3002 European Study Team.

HIV Med. 2001 Jan;2(1):27-34.

PMID:
11737373
[PubMed - indexed for MEDLINE]
6.

Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection.

Steingrover R, Garcia EF, van Valkengoed IG, Bekker V, Bezemer D, Kroon FP, Dekker L, Prins M, de Wolf F, Lange JM, Prins JM.

AIDS Res Hum Retroviruses. 2010 Apr;26(4):379-87. doi: 10.1089/aid.2009.0041.

PMID:
20377419
[PubMed - indexed for MEDLINE]
7.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
[PubMed - indexed for MEDLINE]
8.

Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study.

Grijsen M, Koster G, van Vonderen M, van Kasteren M, Kootstra G, Steingrover R, de Wolf F, Prins J, Nieuwkerk P; Primo-SHM study group.

HIV Med. 2012 Nov;13(10):630-5. doi: 10.1111/j.1468-1293.2012.01020.x. Epub 2012 Apr 25.

PMID:
22533544
[PubMed - indexed for MEDLINE]
9.

Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study.

Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN; CASCADE Collaboration.

Antivir Ther. 2007;12(2):189-93.

PMID:
17503661
[PubMed - indexed for MEDLINE]
10.

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Wyl Vv, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study-SHCS.

PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.

PMID:
22102898
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group.

Lancet. 2007 Aug 4;370(9585):407-13.

PMID:
17659333
[PubMed - indexed for MEDLINE]
12.

Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.

PMID:
16044002
[PubMed - indexed for MEDLINE]
13.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.

PMID:
17352766
[PubMed - indexed for MEDLINE]
14.

A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.

Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA.

Clin Infect Dis. 2005 Feb 15;40(4):594-600. Epub 2005 Jan 26.

PMID:
15712083
[PubMed - indexed for MEDLINE]
Free Article
15.

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L.

PLoS One. 2009;4(5):e5575. doi: 10.1371/journal.pone.0005575. Epub 2009 May 18.

PMID:
19440326
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM; Advanz Study Group.

AIDS Res Hum Retroviruses. 2010 Jul;26(7):747-57. doi: 10.1089/aid.2009.0105.

PMID:
20624069
[PubMed - indexed for MEDLINE]
17.

A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.

Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, Ssali F, Dewar R, Daucher M, Davey RT Jr, Mugyenyi P, Fauci AS, Quinn TC, Dybul MR.

PLoS One. 2010 Apr 22;5(4):e10307. doi: 10.1371/journal.pone.0010307.

PMID:
20442758
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
[PubMed - indexed for MEDLINE]
19.

Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD).

Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG; Asia Pacific HIV Observational Database (APHOD).

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):513-20.

PMID:
19408354
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.

PMID:
15097300
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk